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Abstract
Mutations in the creatine (Cr) transporter (CrT; Slc6a8) gene lead to absence of brain Cr and intellectual disabilities, loss of
speech, and behavioral abnormalities. To date, no mouse model of CrT deficiency exists in which to understand and develop
treatments for this condition. The purpose of this study was to generate a mouse model of human CrT deficiency. We
created mice with exons 2–4 of Slc6a8 flanked by loxP sites and crossed these to Cre:CMV mice to create a line of ubiquitous
CrT knockout expressing mice. Mice were tested for learning and memory deficits and assayed for Cr and neurotransmitter
levels. Male CrT
2/y (affected) mice lack Cr in the brain and muscle with significant reductions of Cr in other tissues including
heart and testes. CrT
2/y mice showed increased path length during acquisition and reversal learning in the Morris water
maze. During probe trials, CrT
2/y mice showed increased average distance from the platform site. CrT
2/y mice showed
reduced novel object recognition and conditioned fear memory compared to CrT
+/y. CrT
2/y mice had increased serotonin
and 5-hydroxyindole acetic acid in the hippocampus and prefrontal cortex. Ubiquitous CrT knockout mice have learning and
memory deficits resembling human CrT deficiency and this model should be useful in understanding this disorder.
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Introduction
The creatine (Cr) transporter (CrT; SLC6a8) is a member of the
solute carrier 6 family that transports Cr into cells in a Na
+,K
+-
dependent manner where it is used as a readily available
phosphate pool to replenish ATP levels [1]. As the CrT is located
on the X-chromosome [2], mutations in the CrT show X-linked
inheritance [3,4]. Males carrying deletions in the CrT show
moderate to severe intellectual disability with significant speech
delay or lack of speech [3–11]. In addition, CrT deficient patients
have increased rates of epilepsy [7]. Patients have increased
urinary Cr/creatinine ratios and no brain Cr peak when examined
by magnetic resonance spectroscopy (MRS) [3]. Cultured
fibroblasts from these patients show Cr uptake only at high levels
(.500 nM) unless transfected with a functional CrT [12].
Supplementation with Cr or the synthesis precursor arginine does
not increase Cr in brain or improve quality of life of affected
patients [6,13]. CrT deficiency is a relatively newly recognized
disorder and is not routinely screened which makes estimates of
the prevalence difficult to determine. Initial estimates are that it
represents ,2% of all X-linked mental retardation of unknown
etiology [14–16].
CrT expression is highest in kidney, heart, skeletal muscle, and
brain [1]. In the adult rat CNS, CrT expression has been localized
to oligodendrocytes and brain capillary endothelial cells [17–19],
which is the likely route of entry for Cr into the brain [20]. In the
mouse brain, CrT has been observed as early as embryonic day 13
[17,19] and postnatal expression is observed in the hippocampus,
neocortex, and basal ganglia [18]. Immunohistochemical studies
show high expression of CrT in the rat brain, particularly in the
CA3 and dentate gyrus regions of the hippocampus [21].
In order to investigate CrT deficiency, we generated a
transgenic mouse with a portion of the CrT gene flanked by loxP
sites. This mouse was used to create ubiquitous CrT knockout
mice mimicking affected patients. Ubiquitous CrT knockout mice
were tested in a variety of tasks, with particular emphasis on tests
of learning and memory. The results show that this model reflects
many of the features of human CrT deficiency.
Methods
Generation of CrT knockout mice
The CrT construct and conditional founder mice were
generated and maintained on a C57BL/6J background through
the University of Cincinnati Embryonic Stem Cell Core according
to standard techniques [22]. Exons 2–4 of the CrT (SLC6A8) gene,
which corresponds to the 2
nd–4
th transmembrane domain of the
protein, were flanked by loxP sites (Figure 1A). Successful
recombination was verified by the presence of the 5.1 kb and
3.8 kb fragments on the Southern blot of the targeted ES cells
(Figure 1B). A ubiquitously expressed flipase (B6;SJL-Tg(ACTFL-
Pe)9205Dym/J mice [23]) was utilized to create the CrT
flox/flox.
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cre)1Cgn/J; Jackson Laboratory, Bar Harbor, ME) was utilized to
create ubiquitous CrT knockout mice. The Cre and Flp were
subsequently removed via breeding. As the CrT is X-linked only males
have a single copy of the CrT gene therefore WT male mice are
referred to as CrT
+/y and knockout mice as CrT
2/y.G e n o t y p i n gw a s
performed using a touchdown PCR protocol: 1) 95uC-5 min; 2) 2
cycles: 95uC-30 s, 60uC-30 s and 72uC-1 min; 3) 20 cycles: 95uC-30 s,
60uC-30 s D-0.5uCe a c hc y c l e ,7 2 uC-1 min; 4) 10 cycles: 95uC-30 s,
50uC-30 s and 72uC-1 min 5) 72uC-10 min. Primers (designated on
Figure 1A) used were AGGTCCAGACAGTAACTACCCTTC,
TGGGTTTGCAGCTTGGTGTTATTGC and TCCTACAC-
CAATACCCCCATAAGC. The product sizes are as follows: CrT
flox:
548 bp; CrT
+: 422; CrT
2: 346 bp (Figure 1C). The vivarium is fully
accredited by the AAALAC and all protocols were approved by the
Institutional Animal Care and Use Committee (Protocol #8C08066).
Behavioral Testing
Sixteen adult males (postnatal day 90–110 at beginning of
testing) of each genotype were used in the behavioral experiment.
Litters were only represented once per genotype. As CrT
deficiency is X-linked only males are consistently affected,
therefore only the male mice were tested. Mice were weighed
once prior to testing. The testing order consisted of: locomotor
behavior (1 day duration), Morris water maze (MWM) cued (6
days) and hidden platform phases (21 days), novel object
recognition (5 days), sociability (1 day), acoustic startle (1 day),
and conditioned fear (3 day). Mice were tested in one task at a time
with the next starting 1 day after the completion of the previous
task for a total of 38 days of testing. In order to minimize circadian
effects, animals were tested during the same time interval each day
(1200–1600 h).
Locomotor behavior
The task assesses exploration and generallocomotor activity [24].
Animals were tested in an automated activity monitor (Accuscan
Electronics, Columbus, OH) as described previously [25–27] for
1 h. Locomotor chambers were 41 cm
2 with 16 LED-photodector
beams across each side of the chamber in the X and Y-planes
(mounted 2 cm above the floor) and another row to detect vertical
movementspositioned 8 cm above the floor. Photocells were spaced
2.5 cm apart. Animals were placed in the chamber for 1 h and
allowed to explore. Dependent measures for locomotor are
measured in number of times the beam is broken.
Morris water maze
The MWM is a test of spatial learning and reference memory
[28]; animals were tested as described previously [25,27]. Prior to
hidden platform testing, visible platform training (cued learning)
was conducted for 6 days. During this phase, curtains were closed
around the maze to obscure prominent distal cues and a 10 cm
diameter platform with an orange ball mounted above it on a brass
rod was placed in a predetermined quadrant. On the first day, 6
trials (90 s) were administered with the platform and start in the
same position; 2 trials per day were given on subsequent days with
the start and platform positions randomized.
The hidden platform portion was conducted in three phases (6
days/phase: acquisition, reversal, and shift) consisting of 4 trials
per day for 6 days for animals to learn the location of the hidden
platform followed by a single probe trial (no platform) on day 7
[28]. Platform diameters were 10 cm for acquisition, 7 cm for
reversal (located in the opposite quadrant), and 5 cm for shift,
(located in one of the adjacent quadrants). Performance was
measured using AnyMaze software (Stoelting Company, Wood
Dale, IL).
Figure 1. Generation of the CrT
flox/flox mice. (A) Schematic of mouse Slc6a8 locus (top), targeting vector (middle), and targeted locus (bottom).
Exons 2-4 were flanked by LoxP sites and the neomyocin cassette was flanked by FRT sites. Neo cassette was excised prior to breeding to any Cre
recombinase expressing mice. (B) Southern blot showing successful recombination in ES cells used for generation of the CrT
flox mice. (C) PCR
products are shown for the respective genotypes. Due to the CrT being located on the X-chromosome, males have one copy of the CrT gene and are
designated as 2/y (left), +/y (center-left) or flox/y (center) while females (center right and right) have two copies of the CrT. Female 2/2 mice are not
generated as there are no CrT deficient females.
doi:10.1371/journal.pone.0016187.g001
Mouse Model of CrT Deficiency
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Novel object recognition (NOR) is a test of short-term memory
[29]. Mice were habituated to the arena (91 cm diameter) for 2
days (10 min/day) followed by 2 days (10 min/day) of habituation
to two identical objects. On the test day, animals were presented
with two new identical objects until 30 s of cumulative observation
time was obtained. One h later memory was tested by presenting
the animal with an identical copy of one of the familiar objects
along with a novel object. A discrimination index was calculated
by subtracting the time observing the familiar object from time
spent observing the novel object.
Sociability
Mice were tested for social preference as described by Crawley
et al. [30]. The test arena (40640 cm) was made of clear acrylic
with three chambers (outer chambers: 17640 cm; inner chamber
Figure 2. Body weight is reduced in CrT
2/y mice while brain weights were unchanged. (A) Body weights were collected prior to behavioral
testing and (B) brain weights were collected from animals following the end of behavioral testing. Data are presented as Mean 6SEM. *** P,0.001, n=16/genotype.
doi:10.1371/journal.pone.0016187.g002
Table 1. Cr levels (Mean 6 SEM) in CrT
+/y and CrT
2/y mice
(n=8/tissue).
Tissue (nM/mg tissue) CrT
+/y CrT
2/y
Brain 18,11662378 BDL
Muscle 21,8236531 BDL
Heart 50,01265345 11,01261612***
Testes 24,7316684 22,0196922*
Kidney 10,82462346 9,73161151
Serum (nM/mL) 275632 12368***
*P,0.05;
***P,0.001 vs. Control. BDL=below detection limit.
doi:10.1371/journal.pone.0016187.t001
Mouse Model of CrT Deficiency
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ment cage for a conspecific of the same-sex (7 cm i.d., stainless
steel rods spaced 1 cm apart) was placed in each outer chamber.
Testing (habituation, social preference, and social novelty) was
initiated by placing the test animal in the center compartment and
leaving them undisturbed for 10 min. Following habituation,
social interaction was tested by placing a mouse in one of the side
compartment cages. Social novelty was tested by placing a second
mouse in the confinement cage in the opposite compartment. Data
were collected using AnyMaze Software (Stoelting Company).
Time in each zone was recorded.
Acoustic startle response
Acoustic startle combined with prepulse inhibition (PPI) was
used as a test of sensory gating [31]. Responses to an acoustic
startle stimulus were measured in an SR Lab apparatus from San
Diego Instruments (San Diego, CA) with a 70 dB background
white noise. Following a 5 min acclimation period, 4 trial types (5
trials each) were administered in a Latin square design over 7 min:
1) no stimulus; 2) stimulus alone (120 db SPL white noise burst)
and prepulses at 3) 70 dB and 4) 76 dB. Startle responses were
recorded for 100 ms following stimulus onset, prepulses preceded
the startle stimulus by 70 ms (onset to onset), and stimuli lasted for
20 ms. Maximum startle amplitude (Vmax) was recorded in units of
voltage change (mV).
Conditioned fear/Conditioned fear extinction
Cued and contextual fear were assessed as described previously
with modification [32]. On day 1, mice were exposed to 30 tones
(82 dB, 2 kHz, 30 s on/off cycle) followed by 3 tone-footshock
pairings (0.5 mA for 1 s). On the following day, animals were
returned to the chamber with no tone or shock presented as a test
of contextual fear. The next day, animals were placed in the
chamber with a novel grid floor. Following 3 min acclimatization,
the tone was presented and freezing behavior scored. Animals
were then exposed to 30 cycles of 30 s with and 30 s without tone
to measure fear extinction. Freezeframe software and Coulbourn
test chambers were used (Coulbourn Instruments, Allentown, PA).
Percent time freezing was analyzed.
Creatine determination
A group of animals not behaviorally tested was assayed for tissue
and serum Cr levels using a colorimetric Cr assay (Cr Assay Kit,
Caymen Chemical, Ann Arbor, MI). Cr levels were normalized to
tissue weight or serum volume. For CNS tissue, whole brain was
used.
Neurotransmitter Assessment
A subset of animals was euthanized following behavioral testing
and the prefrontal cortex (PFC), hippocampus, and neostriatum
were assayed for serotonin (5-HT), dopamine (DA), their
metabolites, and norepinephrine (NE) using HPLC-ECD as
described previously [33].
Statistical Analysis
Data were analyzed using general linear model analysis of
variance (ANOVA) (Proc GLM; SAS Institute, Cary, NC). For
data with a repeated measure factor, data were analyzed using
mixed models (Proc Mixed) with Kenward-Rodger degrees of
freedom that can be fractional. Covariance structures were
checked for best fit and the autoregressive (AR(1)) covariance
structure used. Significant (P,0.05) interactions were analyzed
using slice-effect ANOVAs at each level of the repeated measure
factor. Data are presented as means 6 standard error of the mean
(SEM) or as least square (LS) Mean + LS SEM.
Results
Body Weight
In order to determine the effects of the deletion of CrT on body
and brain weights, animals were weighed prior to testing and
brains were weighed after behavioral testing. CrT
2/y mice showed
reduced body weights compared to CrT
+/y mice (F(1,30)=205.3,
P,0.001; Figure 2A). Brain weight was not altered (Figure 2B).
Creatine Levels
CrT deficient patients show no Cr in the brain as determined by
MRS [3]. In order to determine the effectiveness of the CrT
2/y
model, Cr levels were measured by colorimetric assay in various
tissues. In brain and muscle, Cr levels were below detection limits
in CrT
2/y mice (Table 1). Reductions of Cr were observed in
the heart (F(1,15)=48.40, P,0.001), serum (F(1,15)=20.08,
P,0.001), and testes (F(1,15)=5.57, P,0.05) of CrT
2/y mice
compared with CrT
+/y mice, with no difference in kidneys. This
suggests that CrT
2/y mice have a similar biochemical phenotype
compared to CrT deficient patients.
Locomotor Activity
Locomotor activity was assessed in order to determine general
activity levels and to determine if reduced Cr levels in muscle
affected normal locomotion in CrT
2/y mice. CrT
2/y mice showed
Figure 3. Initial hypoactivity and increased peripheral actvity in CrT
2/y mice. Locomotor activity was measured for 1 h in a novel
environment. Top panel represents total activity; bottom panel is activity in the periphery of the locomotor chamber. The inset in the bottom panel
represents the main effect of gene. Data are presented as LSMeans 6 SEM. *P,0.05, n=16/genotype.
doi:10.1371/journal.pone.0016187.g003
Figure 4. CrT
2/y mice show deficits during the visible platform
phase of the MWM. The visible platform phase consisted of 6 trials on
day 1 followed by 2 trials/day for 5 days. While the latencies were
longer in CrT
2/y mice for each day compared with CrT
+/y mice the
percent improvement across days was similar between the genotypes.
Data are presented as LSMeans 6 SEM. n=16/genotype.
doi:10.1371/journal.pone.0016187.g004
Mouse Model of CrT Deficiency
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interval (F(11,320)=2.30, P,0.01; Figure 3, top)], however they
were more active in the periphery compared with CrT
+/y mice
after the first interval [genotype (F(1,57.1)=4.53, P,0.05,
Figure 3, bottom)]. No effect of genotype was observed for center
region exploration. There were no differences observed in vertical
movements (rearing) between CrT
+/y and CrT
2/y mice.
Morris Water Maze-Visible Platform
As CrT deficient patients show global intellectual deficits, CrT
2/y
mice were tested in several learning tasks. Visible platform testing in
the MWM was used to determine if CrT
2/y mice had sensorimotor
or motivational deficits in escaping the maze. CrT
2/y mice had a
longer latency to find the platform compared with CrT
+/y mice
[genotype (F(1,45.7)=21.23, P,0.001; Figure 4)]. As animals
showed an effect of swim speed during hidden platform trials,
percent change during the visible phase for each day after day-1 was
calculated. No difference between CrT
2/y and CrT
+/y mice was
observed using this index of improvement across days (Mean 6 SEM
improvement: 4069% CrT
+/y vs 47610% CrT
2/y) indicating that
CrT
2/y mice had similar performance improvement compared to
WT controls. The similar improvement observed between CrT
2/y
and CrT
+/y mice suggests that motivation and vision were intact in
the CrT
2/y mice and the difference observed is the result of reduced
swim speed in the CrT deficient mice.
Morris Water Maze-Hidden Platform
The hidden platform test of the MWM was used to assess spatial
learning and reference memory. Three phases of the test were
performed: acquisition (initial learning), reversal (platform in the
Figure 5. CrT
2/y mice have spatial learning and memory deficits. Path length for the (A) Acquisition, (C) Reversal, and (E) Shift phases of the
MWM; each phase consisted of 4 (90 s) trials/day for 6 consecutive days. Probe trials of 30 s with the platform removed were conducted on the 7
th
day following the (B) Acquisition, (D) Reversal, and (F) Shift phases. Data are presented as LSMeans 6 SEM. ***P,0.001, **P,0.01; n=16/genotype.
doi:10.1371/journal.pone.0016187.g005
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quadrant adjacent to where it was during reversal) and with
platform size reduced for each phase after acquisition in order to
make the task progressively more difficult. As there was a main
effect of genotype on swim speed (all P,0.001) in all phases of the
hidden platform, path length was analyzed because it is
independent of swim speed.
Acquisition. CrT
2/y mice had longer path lengths comp-
ared with CrT
+/y mice [genotype (F(1,51.4)=28.72, P,0.001,
Figure 5A)]. For the probe trial, CrT
2/y mice had a greater average
distance from the platform [genotype (F(1,30)=24.4, P,0.001,
Figure 5B)] and a lower percent distance travelled in the target
quadrant compared with CrT
+/y mice (F(1,30)=24.74, P,0.001;
LS Means 6 SEM: CrT
+/y:4 7 . 1 63.8%, CrT
2/y: 25.063.3%).
Reversal. CrT
2/y mice had longer paths to the platform than
CrT
+/y mice [genotype (F(1,47.3)=7.68, P,0.01, Figure 5C)].
For the probe trial, CrT
2/y mice had a greater average distance
from the platform [genotype (F(1,30)=17.8; P,0.001, Figure 5D)]
and a lower percent distance travelled in the target quadrant
compared with CrT
+/y mice (F(1,30)=16.25, P,0.001; LS Means
6 SEM: CrT
+/y: 40.562.8%; CrT
2/y: 19.864.3%).
Shift. No main effect of genotype was observed during the shift
phase of testing (Figure 5E). CrT
2/y mice had shorter path lengths
on day 1 of shift compared with CrT
+/y mice [genotype X day
interaction (F(5,115)=3.34; P,0.01)]. For the probe trial, CrT
2/y
mice had a greater average distance from the platform [genotype
(F(1,30)=8.59, P,0.01; Figure 5F)] and a lower percent distance
travelled in the target quadrant compared with CrT
+/y mice
(F(1,30)=5.84 P,0.05; LS Means 6 SEM: CrT
+/y:3 8 . 5 65.0% vs.
CrT
2/y: 24.862.7%). The data from the shift phase indicate that
neither the CrT
+/y or CrT
2/y mice were able to learn well under
these more demanding conditions and the lack of difference
between genotypes appears to be caused by this final phase being
excessively difficult. This can be seen by comparing the path length
of CrT
+/y mice across phases. It is evident that both genotypes
showed reduced performance with each subsequent phase until
during the third phase even CrT
+/y controls showed poor learning.
Novel Object Recognition
NOR is a test of short-term, hippocampally-dependent
memory. CrT
2/y mice spent less time attending to the novel
object than CrT
+/y mice [genotype (F(1,30)=7.30, P,0.05,
Figure 6)]. CrT
2/y mice investigated the objects and reached
the 30 s criterion, therefore, the visual system of CrT
2/y mice are
sufficiently intact that they can see and recognize the objects
adequately to respond to them appropriately.
Acoustic Startle Response with Prepulse Inhibition
The measurement of acoustic startle requires the animal to
deflect the platform on which the holding cylinder is mounted
against a load cell mounted underneath, therefore, body mass is a
factor in the measurement of the amplitude of the response. In
order to adjust for the reduced body mass of the CrT
2/y mice,
body weight was used as a covariate in the analysis. There were no
differences in acoustic startle response with or without prepulse
inhibition using weight as a covariate (Figure 7).
Sociability
As CrT deficient patients have been reported to have some
autistic-like features, CrT
2/y mice were tested for social preference
for conspecifics. No differences were observed in initial social
preference for a conspecific stranger mouse (Figure 8A) or a
second stranger mouse located in a different part of the apparatus
during the second or novelty phase of the test (Figure 8B). CrT
+/y
and CrT
2/y mice showed equivalent preference for stranger mice
during both phases.
Conditioned fear and extinction
CrT
2/y mice were tested for emotional memory using a
conditioned fear paradigm. CrT
2/y mice spent less time freezing
than CrT
+/y mice in response to conditioning (contextual fear) on
day-2 [genotype (F(1,23)=1.78, P,0.05, Figure 9)]. CrT
2/y mice
spent less time freezing in response to tone (cued fear) on day 3
than CrT
+/y mice [genotype (F(1,24)=4.71, P,0.05, Figure 9)].
No differences were observed in the rate of cued fear extinction.
Neurotransmitters
In order to characterize general brain systems, monoamine
neurotransmitter levels were assessed in brain regions of CrT
+/y
Figure 6. CrT
2/y mice show deficits in object recognition
memory. The novel object recognition test was conducted 1 h
following familiarization. The novel object discrimination index was
determined by subtracting the percent time with the familiar object
from the percent time with the novel object. Data are Mean 6 SEM.
*P,0.05, n=16/genotype.
doi:10.1371/journal.pone.0016187.g006
Figure 7. Acoustic Startle with prepulse inhibition. Startle
response was measured following exposure to a 120 dB tone. For
prepulse (PP) inhibition, tone was preceded by a softer tone of either 70
or 76 dB. As the size of the animal affects the ability to move the
chamber, weight was used a covariate in the analysis of startle
response. No differences were noted in startle response with weight as
a covariate. Data are Mean 6 SEM; n=16/genotype.
doi:10.1371/journal.pone.0016187.g007
Mouse Model of CrT Deficiency
PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e16187and CrT
2/y mice. In the PFC, 5-HT levels were increased in
CrT
2/y mice (F(1,14)=6.0, P,0.05; Table 2) compared with
CrT
+/y mice.
In the hippocampus, 5-HT (F(1,16)=5.81, P,0.05), 5-hydro-
xyindoleacetic acid (5-HIAA) (F(1,16)=25.5, P,0.001), and the 5-
HIAA/5-HT ratio (F(1,16)=7.48, P,0.05) were increased in
CrT
2/y mice compared with CrT
+/y mice. NE levels were
unchanged.
In the neostriatum, CrT
2/y mice showed a trend towards
increased DA (F(1,16)=3.64, P,0.10); they had increased levels of
5-HIAA (F(1,16)=12.41, P,0.01) and 5-HIAA/5-HT
(F(1,16)=11.63, P,0.01) compared with CrT
+/y mice. No
changes were observed for 5-HT, DOPAC, DOPAC/DA,
HVA, or NE in the neostriatum.
Discussion
In humans, loss of function of the CrT leads to intellectual
impairment, loss of language, and autistic-like behavioral abnor-
malities, and no treatment is available [3,4,6,7,9,10,13]. In order
to model this disorder and also understand the role of Cr in the
brain, we created CrT
2/y mice. The lack of Cr in many tissues of
the CrT
2/y mice shows that the recombination resulted in a
successful disruption of the CrT gene.
Human CrT deficient patients show no brain Cr using MRS
[3]. Similarly, Cr is absent in the brain of CrT
2/y mice. The
results of this study suggest that the mouse brain is unable to
synthesize Cr despite having the requisite mechanisms [19,34]. In
addition, CrT
2/y mice show Cr reductions in muscle, which is in
contrast with case reports of two CrT deficient patients who had
either the presence of Cr [6] (although levels were not determined)
or normal Cr levels in muscle [35]. It is possible that these patients
had a mutation that allowed for the expression of a CrT splice
variant, and this is supported by mutation analysis of these patients
that showed the mutations occurred outside of the known splice
variants for the CrT [36,37]. Additional studies in human CrT
patients using MRS could provide useful information on the
relationship between the mutations in the CrT and the presence of
Cr in muscle. The only tissue in which Cr levels appear to be
normal was in kidney, which could be due to the role of the kidney
in Cr synthesis or elimination. It is likely that the reductions in
serum Cr levels are due to the lack of absorption of Cr from the
gut since the CrT is expressed in the small intestine [38], which is
the hypothesized route of Cr absorption from the diet.
Similar to human CrT patients, CrT
2/y mice show cognitive
impairments across a variety of learning and memory tests. CrT
2/y
mice show spatial learning and memory deficits during the first two
phasesoftheMWM.WhiletheCrT
2/ymicewereslowerswimmers
than CrT
+/y mice, swim speed does not affect path length; therefore
this measure is not confounded by performance effects. CrT
2/y
mice showed no deficit during the shift phase of the MWM;
however, this was because even the CrT
+/y control mice could not
learn this phase adequately, precluding the detection of differences
between genotypes. Nonetheless, on probe trials during this third
phase, the CrT
2/y mice were impaired, therefore, even the little
they were able to learn during this phase they could not remember
as well as CrT
+/y.
Figure 8. Social preference test. Mice were allowed to investigate a conspecific (A) inside a holding cage on one side of the apparatus versus an
empty holding cage on the opposite side. Immediately afterward they were tested for social novelty (B) with a second conspecific placed in the
holding cage on the opposite side from the original mouse. Mice were given 10 min to explore the arena during each test. Data are Mean 6 SEM;
n=16/genotype.
doi:10.1371/journal.pone.0016187.g008
Figure 9. CrT
2/y mice have reduced contextual and emotional
memory compared with CrT
+/y mice. Mice were exposed to tone-
shock pairings on day 1 of the conditioned fear test. On day 2
(contextual) they were tested for freezing in the same environment with
no tone for 6 min. On the third day (conditioned), the floor was
replaced with a novel floor. After 3 min of habituation, mice were
exposed to the tone for 3 min and freezing measured. Data are
presented as Mean 6 SEM. *P,0.05; n=11 CrT
+/y mice, n=13 CrT
2/y
mice.
doi:10.1371/journal.pone.0016187.g009
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memory deficits. For example, CrT is highly expressed in the retina
[39], which could lead to visual problems in CrT
2/y mice. The
improvement in the cued version of the MWM as well as the animals’
readily observing and responding to objects during the NOR task (no
animal failed to accumulate the 30 s observation criterion) suggests that
the visual system is not disrupted in the CrT
2/y mice sufficiently to
impair visually-mediated tests. In addition, the CrT
2/y mice acquired
the platform’s location as shown by CrT
2/y mice having an average
l a t e n c yo f4 6 so u to fa9 0 st r i a lduring the acquisition phase,
suggesting that distal visual cues were used by the CrT deleted mice to
navigate to the platform. This suggests that neither sensorimotor nor
motivational impairments contributed to the observed deficits.
During the probe trials, CrT
2/y mice showed impaired reference
memory compared with CrT
+/y mice. In addition to the probe
trials, mice were assessed for memory in the NOR and conditioned
fear tests. CrT
2/y mice showed reduced memory in both of these
tasks. The deficits in memory across tasks combined with the
learning trials in the MWM suggest that CrT
2/y mice have a
general cognitive impairment. In humans, the type of learning
deficit has not been characterized in detail because the phenotype
prevents systematic assessment (Byars, personal communication).
There appears to be a disruption of the serotonergic system in
CrT
2/y mice as evidenced by increases in 5-HT in hippocampus
and prefrontal cortex along with increased 5-HT turnover in the
neostriatum and hippocampus. It has been shown that serotonergic
drugs such as fluoxetine and paroxetine increase Cr kinase activity
[40,41], suggesting a relationship between 5-HT and Cr. Addition-
ally, exposure to 5-HT, the 5-HT1A receptor agonist 8-hydroxy-
N,N-dipropyl-2-aminotetralin, or fluoxetine increases the speed of
anterograde mitochondrial transport in hippocampal neurons,
while serotonergic antagonism slows mitochondrial transport [42].
Further, there have been recent reports suggesting that 5-HT may
play a role in mitochondrial activity, as 5-HT receptor agonists
increase ATP and ATP synthase b levels as well as increase basal
cellularrespirationinkidneycells[43].Itispossible thattheneurons
of the PFC and hippocampus increased 5-HT activity in response to
a reduction in cellular energy sources. As increases in 5-HT have
been shown to alter neuronal structure and behavior [44,45], it is
possible that the 5-HT changes are involved in the behavioral
effects, including anxiety. CrT
2/y mice spend more time in the
periphery of the locomotor chamber with no change in centraltime;
since central movement reflects anxiety, the data suggest that
anxietyisnotaltered inthesemice.Additionaltestsofanxietywillbe
required to address this in greater depth, including testing for a
relationship between these behaviors and changes in 5-HT.
In sum, the CrT
2/y mouse provides a tool for studying the
relationship between Cr and 5-HT. More broadly, CrT
2/y mice
exhibit cognitive deficits similar to those seen in CrT deficient
patients and as such provides a model with good fidelity to the
human condition suitable to test potential therapies for this
currently untreatable disorder.
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